Market Size (2023)
$813.58M
Vertical: HealthcareBase Year: 2023
Market Size (2023)
$813.58M
Projected (2032)
$1.26B
CAGR (2019–2032)
4.1%
Key Players
10+
This report covers Multiple Sclerosis Treatment Devices Market with forecasts from 2019 to 2032. 10 key companies are profiled.
The Multiple Sclerosis Treatment Devices Market market is projected to grow at a CAGR of 4.1% from 2019 to 2032.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMultiple Sclerosis Treatment Devices Market
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Million)
Analysis of Multiple Sclerosis Treatment Devices Market from 2019 to 2032. Covers North America, Europe, Asia-Pacific, South America, Middle East and Africa.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2023
Historical Period
2019 – 2022
Forecast Period
2024 – 2032
Primary Interviews
150+
Historical data (2019–2023) and forecast period (2023–2032)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMichael Porter’s Five Forces model is a framework to study the Global Multiple Sclerosis Treatment Devices Market. Strategic business managers trying to gain an edge over competing firms in the Global Multiple Sclerosis Treatment Devices Market can utilize this model to better comprehend the industry in which the firm operates. The components of each of the forces and the degree of impact of each component in the context of the Global Multiple Sclerosis Treatment Devices Market have been broken down and analyzed.
PORTER’S FIVE FORCES Analysis: Global Multiple Sclerosis Treatment Devices Market
Threat of New Entrants
The threat of new entrants is moderate, primarily due to the high costs of research and development (R&D), regulatory hurdles, and the dominance of established players in the market. Developing MS treatment devices such as electrical stimulation devices and neurostimulation devices requires significant investment in clinical trials, FDA and EMA approvals, and technological innovation. While partnerships with health-tech startups, academic research institutions, and funding from government or private investors may lower the barriers, the market remains challenging for new entrants due to intellectual property protections, complex manufacturing requirements, and strong brand loyalty among healthcare providers.
Bargaining Power of Suppliers
The suppliers in the Global Multiple Sclerosis Treatment Devices Market are the manufacturers of multiple sclerosis treatment devices help manage symptoms, improve mobility, enhance rehabilitation, and support neurological function in MS patients. The bargaining power of suppliers is a crucial factor in the Global Multiple Sclerosis Treatment Devices Market and determines the industry's strength. Many suppliers are currently present in the market due to the availability of a huge patient pool, high demand for of multiple sclerosis treatment devices by patients and increasing government support. The existing key companies capture significant market share and monitor the cost of the products. The switching cost of these suppliers is moderate because suppliers tend to enter long-term associations, partnerships, and deals with other product manufacturing companies. Thus, the overall bargaining power of suppliers in the Global Multiple Sclerosis Treatment Devices Market is expected to be moderate during the forecast period.
Threat of Substitutes
The threat of substitutes is moderate, as pharmaceutical therapies remain the primary treatment option for multiple sclerosis. Disease-modifying drugs (DMDs), corticosteroids, and biologics are widely used to slow MS progression and manage symptoms, reducing the immediate need for treatment devices. However, the limitations of drug therapies, such as side effects, high costs, and variable patient responses, have driven interest in multiple sclerosis treatment devices. As awareness and clinical validation of these devices grow, their acceptance as effective adjunct or standalone therapies is expected to rise, reducing dependency on traditional pharmacological treatments.
Bargaining Power of Buyers
Buyers in the Global Multiple Sclerosis Treatment Devices Market, such as hospitals and ASC’s. These buyers could have moderate bargaining power because the products in this industry are highly specialized and critical for patient care. Healthcare providers prioritize quality and reliability over price, reducing their bargaining leverage.
Intensity of Rivalry
The degree of competition in the Global Multiple Sclerosis Treatment Devices Market is high, owing to the presence of a large number of prominent players. Moderate product differentiation among existing players increases the intensity of rivalry in the market. Competition is based on factors such as product efficacy, pricing, innovation, and brand reputation. The industry is characterized by continuous research and development efforts to introduce new and improved multiple sclerosis treatment devices. Key players engage in strategic partnerships, acquisitions, and product differentiation to maintain or enhance their market positions. Thus, the intensity of rivalry in the Global Multiple Sclerosis Treatment Devices Market is expected to be high during the study period.
Impact of covid-19 on the Global Multiple Sclerosis Treatment Devices Market
The COVID-19 pandemic significantly impacted the global multiple sclerosis treatment devices market, disrupting supply chains, delaying clinical trials, and altering healthcare priorities. During the initial phases of the pandemic, lockdowns and restrictions on non-emergency medical visits led to reduced access to MS treatment devices, particularly for patients requiring routine monitoring and rehabilitation. Hospitals and clinics redirected resources toward managing COVID-19 cases, delaying elective procedures and non-urgent neurological interventions. Additionally, disruptions in manufacturing and logistics caused temporary shortages of essential medical devices used in MS treatment, such as neurostimulation devices and mobility aids.
However, the pandemic also accelerated the adoption of telemedicine and remote monitoring solutions, enabling MS patients to access care while minimizing in-person visits. The increased emphasis on digital health contributed to market resilience. Furthermore, as healthcare systems adapted to pandemic-related challenges, investments in neurological care rebounded, leading to a gradual recovery in the MS treatment devices market. Moving forward, the market is expected to benefit from continued technological advancements and the integration of digital solutions to enhance MS patient management.
SCOPING, METHODOLOGY AND MARKET STRUCTURE
SCOPING, METHODOLOGY AND MARKET STRUCTURE
Market estimates by geography (2032)
InsightEurope leads with $527.04M by 2032, while Asia-Pacific is projected to grow fastest at a 5.5% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2019 | 2023 | 2032 | CAGR | SHARE |
|---|---|---|---|---|---|
| North America | $243.56M | $295.85M | $391.93M | 3.7% | 31% |
| Europe | $314.29M | $390.15M | $527.04M | 4.1% | 42% |
| Asia-Pacific | $128.47M | $176.67M | $259.09M | 5.5% | 21% |
| South America | $36.60M | $42.58M | $54.35M | 3.1% | 4% |
| Middle East and Africa | $23.98M | $26.56M | $31.47M | 2.1% | 2% |
| Total | $746.90M | $931.81M | $1.26B | 4.1% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.

Analytical insights on Multiple Sclerosis Treatment Devices Market covering market dynamics, competitive landscape, and strategic outlook.
The Multiple Sclerosis Treatment Devices Market market is projected to reach $1.26B by 2032, growing at 4.1% CAGR.
Increasing Prevalence of Multiple Sclerosis (MS)
The rising prevalence of Multiple Sclerosis (MS) worldwide is a key factor driving the demand for MS treatment devices. MS, a chronic autoimmune disease affecting the Central Nervous System (CNS), has seen a significant increase in diagnosed cases over the past few decades. According to the Atlas of MS 2023, published by the Multiple Sclerosis International Federation (MSIF), an estimated 2.9 million people globally were living with MS, up from 2.3 million in 2013, reflecting a rising burden on healthcare systems. The prevalence and incidence of MS vary across regions, with North America and Europe having the highest rates. Canada reports approximately 288 cases per 100,000 people, making it one of the most affected countries, while in the United States, it is estimated that nearly one million people are living with MS. In Europe, Northern countries such as Norway, Sweden, and the UK report prevalence rates of 150–200 cases per 100,000 people. The disease is significantly more common in women, with a female-to-male ratio of nearly 3:1, further influencing market trends as gender-specific treatment approaches gain traction.
The increasing prevalence of MS is fueling demand for advanced treatment solutions, including neurostimulation devices, wearable rehabilitation technologies, and others, which help manage symptoms such as spasticity, gait disorders, and chronic pain. Additionally, improved diagnostic capabilities due to advancements in imaging techniques like MRI-based lesion tracking and biomarker research are leading to earlier and more accurate diagnoses, further driving the adoption of treatment devices. The rising global MS burden has also led to increased healthcare investments, government initiatives, and funding for innovative medical technologies, positioning the MS treatment devices market for sustained growth.
Advancements in neurostimulation and wearable devices
Advances in neurostimulation and wearables are revolutionizing how multiple sclerosis (MS) can be treated for patients to seek new alternatives and reduce their symptoms and discomfort levels. Neurostimulation technologies, such as transcutaneous electrical nerve stimulation (TENS), spinal cord stimulation (SCS), and deep brain stimulation (DBS), are gaining traction for their ability to modulate neural activity and alleviate symptoms like spasticity, chronic pain, and muscle weakness. Recent developments in non-invasive neuromodulation techniques, such as transcranial magnetic stimulation (TMS) and vagus nerve stimulation (VNS), have shown promising results in improving motor function and cognitive impairment in MS patients. Artificial intelligence (AI) and machine learning have further expanded the adaptability of neurostimulation devices by tailoring treatments according to real-time feedback from the patient.
At the same time, wearable devices have changed MS management through continuous monitoring and rehabilitation support. The smart exoskeletons and robotic-assisted gait trainers significantly improve the mobility of patients with severe motor impairments, while sensor-based wearables such as smart insoles, motion-sensing bands, and electromyography devices enable real-time tracking of gait patterns, muscle activity, and fatigue levels. Companies are now focusing more on the development of smart textiles with embedded sensors that can sense minute changes in movement, temperature, and neurological function, allowing for early intervention and better management of disease. Wearable electrostimulation devices, such as functional electrical stimulation (FES) systems, are being increasingly adopted to assist MS patients overcome walking difficulties by stimulating specific muscle groups. Moreover, cloud-based remote monitoring platforms integrated with these devices are allowing healthcare providers to track disease progression and adjust treatment strategies without frequent hospital visits, improving patient compliance and reducing healthcare costs. With continued research and innovation, neurostimulation and wearable devices are expected to become integral components of personalized MS treatment, addressing both mobility challenges and symptom fluctuations while enhancing overall patient independence.
The rising collaborations between healthcare providers and technology firms are playing a crucial role in advancing Multiple Sclerosis (MS) treatment devices, leading to more effective, accessible, and patient-centric treatment solutions. As MS is a chronic neurological disorder with progressive symptoms affecting mobility, muscle control, and neurological function, partnerships between hospitals, medical device manufacturers, and health-tech companies are driving innovation in neurostimulation, rehabilitation, and assistive treatment devices that improve patient outcomes. One of the essential fields of mutual cooperation is developing next-generation neurostimulation devices. Healthcare providers are in close collaboration with medical technology firms specializing in spinal cord stimulation, transcranial magnetic stimulation, and vagus nerve stimulation to explore non-invasive and implantable neurostimulation therapies for MS patients. Collaborations are also driving innovation in wearable functional electrical stimulation (FES) devices, which assist MS patients with gait and mobility challenges. Medical device manufacturers are working alongside rehabilitation specialists and physiotherapists to develop smart FES systems that deliver targeted electrical impulses to weak or paralyzed muscles, improving walking ability.
For example, companies like Bioness and Ottobock have partnered with neurology-focused rehabilitation centers to introduce intelligent, sensor- based FES le braces that adapt to a patient’s movement patterns in real time, enhancing muscle coordination and reducing the risk of falls. Another significant achievement that has resulted from technology-healthcare partnerships is the integration of AI-driven digital treatment platforms in MS therapy. Companies specializing in AI-based neuromodulation and remote therapy management are teaming up with neurology clinics to develop real-time patient monitoring solutions that can track disease progression and adjust the parameters of the treatment accordingly. For instance, NeuroMetrix, in collaboration with leading MS specialists, has developed Quell, a wearable neuromodulation device that provides adjustable, AI-driven pain relief therapy for MS patients suffering from chronic pain and muscle discomfort. Such partnerships are transforming the landscape of MS treatments, with all patients accessing up-to-date neurostimulation, rehabilitation, and assistive treatment devices, enhancing quality of life. Increasing the adoption of AI-driven, cloud-connected, and wearable treatment devices will have health care providers and technology companies continuously working to present innovative, cost-effective, and patient-friendly solutions for the global market of MS treatments.
Limited awareness and accessibility in developing regions
There are few awareness and access of MS treatment devices in developing regions, which are the main restraints that prevent the extensive use of advanced neurostimulation and rehabilitation technologies. In most low- and middle-income countries, the proper diagnosis and disease awareness lead to delayed or missed treatment opportunities for patients, who are thus prevented from accessing innovative MS management solutions. Healthcare infrastructure in these regions often lacks specialized neurology centers, trained professionals, and advanced diagnostic facilities, leading to underreporting of MS cases and limited demand for treatment devices. Additionally, low physician awareness and inadequate training on the benefits of neurostimulation and wearable rehabilitation technologies further restrict their usage, as many healthcare providers continue to rely on conventional therapies such as physical therapy and pharmaceutical interventions rather than advanced medical devices.
Accessibility challenges are further exacerbated by economic disparities and insufficient insurance coverage, making it difficult for patients to afford high-cost treatment devices. In most African, South Asian, and other developing regions, limited government funding for neurological disorders leads to weak reimbursement frameworks, which leaves MS patients with very few choices for financing. In addition, supply chain limitations, import controls, and regulatory barriers make it difficult for international manufacturers to bring leading-edge MS treatment devices into these markets. Rural areas face an even greater accessibility gap, with inadequate healthcare infrastructure, poor transportation networks, and lack of telemedicine support, further limiting patient access to essential MS care. Addressing these barriers through awareness campaigns, physician training programs, policy reforms, and increased investment in neurological healthcare infrastructure will be crucial in expanding the reach of MS treatment devices and improving outcomes for patients in underserved regions.
The rising collaborations between healthcare providers and technology firms are playing a crucial role in advancing Multiple Sclerosis (MS) treatment devices, leading to more effective, accessible, and patient-centric treatment solutions. As MS is a chronic neurological disorder with progressive symptoms affecting mobility, muscle control, and neurological function, partnerships between hospitals, medical device manufacturers, and health-tech companies are driving innovation in neurostimulation, rehabilitation, and assistive treatment devices that improve patient outcomes.
One of the essential fields of mutual cooperation is developing next-generation neurostimulation devices. Healthcare providers are in close collaboration with medical technology firms specializing in spinal cord stimulation, transcranial magnetic stimulation, and vagus nerve stimulation to explore non-invasive and implantable neurostimulation therapies for MS patients. Collaborations are also driving innovation in wearable functional electrical stimulation (FES) devices, which assist MS patients with gait and mobility challenges. Medical device manufacturers are working alongside rehabilitation specialists and physiotherapists to develop smart FES systems that deliver targeted electrical impulses to weak or paralyzed muscles, improving walking ability. For example, companies like Bioness and Ottobock have partnered with neurology-focused rehabilitation centers to introduce intelligent, sensor-based FES leg braces that adapt to a patient’s movement patterns in real time, enhancing muscle coordination and reducing the risk of falls.
Another significant achievement that has resulted from technology-healthcare partnerships is the integration of AI-driven digital treatment platforms in MS therapy. Companies specializing in AI-based neuromodulation and remote therapy management are teaming up with neurology clinics to develop real-time patient monitoring solutions that can track disease progression and adjust the parameters of the treatment accordingly. For instance, NeuroMetrix, in collaboration with leading MS specialists, has developed Quell, a wearable neuromodulation device that provides adjustable, AI-driven pain relief therapy for MS patients suffering from chronic pain and muscle discomfort.
Such partnerships are transforming the landscape of MS treatments, with all patients accessing up-to-date neurostimulation, rehabilitation, and assistive treatment devices, enhancing quality of life.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 106 companies operating in the Multiple Sclerosis Treatment Devices Market market, including revenue, employee count, and market positioning where available.
Showing 106 of 106 companies
Boston Scientific Corporation
Company Headquarters: Massachusetts, US Founded: 1979 Workforce: ~36,000 Company Working: Boston Scientific Corporation is a worldwide developer, manufacturer, and marketer of medical devices used in a range of interventional medical specialties. The company collaborates with healthcare professionals to develop a broad portfolio of meaningful innovations that improve outcomes, reduce costs, and increase efficiencies. Its product portfolio is majorly divided into endoscopy, interventional cardiology, neuromodulation, peripheral interventions, rhythm management, and urology & pelvic health. In addition, Boston Scientific serves hospitals, clinics, outpatient facilities and medical offices across the world. Boston Scientific Corporation's manufacturing facilities are located across Malaysia, the US, and Ireland. Apart from this, it has a presence in countries like Japan, the Netherlands, France, Poland, India, China, Turkey, South Africa, and Singapore.
Biotronik
Company Headquarters: Berlin, Germany Founded: 1963 Workforce: ~9,000 Company Working: Biotronik is a leading global medical device company with products and services that improve and save the lives of patients suffering from endovascular and cardiovascular diseases. The company’s technologies enable physicians around the world to provide patients the highest standard of care. Its medical devices are created by engineers and designers in Germany, the US, Switzerland, and Singapore. The company is a Golden Goose in the US because of its medium to strong market share, strong profit margins, and slower revenue growth than some of its competitors in the Medical Device Manufacturing industry, where it accounts for an estimated 0.5% of total industry revenue. The company research, develops, and manufactures in technologically advanced countries, including Germany, Switzerland, the US, and Singapore.
Enovis
BTL
Bayer AG
Saluda Medical PTY Ltd.
8 interactive charts drawn from the Multiple Sclerosis Treatment Devices Market dataset — market size, regional splits and each segment breakdown. Open one to read its full data table and download it.
Global Multiple Sclerosis Treatment Devices Market By Region
Global Multiple Sclerosis Treatment Devices Market By Distribution Channel
Global Multiple Sclerosis Treatment Devices Market By Treatment Device
Global Multiple Sclerosis Treatment Devices Market By TYPE
Global Multiple Sclerosis Treatment Devices Market By Country
Global Multiple Sclerosis Treatment Devices Market By End Userl Usd Mn | 2019-2032
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence